Loading stock data…
Fennec Pharmaceuticals Inc (FENC)
$12.45+0.06 (+0.48%)
Market ClosedLast close Sep 8
Fennec Pharmaceuticals Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fennec Pharmaceuticals Inc. in the Healthcare sector is trading at $12.45 with a market capitalization of $315M. Wall Street consensus targets $17.67 (6 analysts), implying a +41.9% move over the next 12 months. The stock is currently near its 52-week high of $13.25, remaining 43.8% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +41.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.11M↑ | $13.78M↑ | $12.46M↑ | $9.65M↑ | $8.75M |
| Gross Profit | $14.54M↑ | $12.01M↑ | $11.80M↑ | $8.69M↑ | $8.38M |
| Operating Income | -$119,000↑ | -$2.58M↓ | -$201,000↑ | -$2.73M↓ | -$821,000 |
| Net Income | $201,000↑ | -$4.79M↓ | -$638,000↑ | -$3.15M↓ | -$1.17M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pedia...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$314.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.23%
Volume
Today's trading volume
256,030
Recent News
Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views
Fennec Pharmaceuticals is back in focus after analysts lifted their fair value estimate from US$15.33 to US$17.67 per share, pointing to a higher assessed equity value for the stock. Recent commentary links this change to stronger than expected PEDMARK revenue, broader use across several tumor types, and updated views on operating leverage that are feeding into refreshed models. As you read on, you will see how this evolving narrative could shape the way you track Fennec Pharmaceuticals from...
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ...
Fennec Pharmaceuticals Inc (FENC) reports a 78% surge in Q2 2026 net product sales to $17.1 million, achieving record EBITDA and positive EPS amid aggressive commercial expansion.
Adherex Technologies Q2 Earnings Call Highlights
Adherex Technologies (NASDAQ:FENC), operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise. Chief Executive Officer Jeff Hackman said t
Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares jumped 7.